-
PROVIDERS
Now Available: xT CDx, FDA-Approved Assay
Discover xT CDx, the FDA-approved assay delivering comprehensive insights through tumor + normal DNA sequencing
-
LIFE SCIENCES
ENROLL NOW
Tempus 3D Tumor Organoid (TO) Screen Evaluate the efficacy of preclinical compounds, including small molecules, monoclonal antibodies (mAbs), peptides, and ADCs. Space is limited—enroll by March 31, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
06/26/2023
Roswell Park Comprehensive Cancer Center
Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer.
FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions.
This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023.
-
02/13/2025AI & ML in action: Real-time advances in precision medicine
Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine. Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. Experience Tempus Lens in action, with an exclusive live demonstration of our newest AI advancements, and hear perspectives on AI's expanding role in healthcare and its transformative potential.
Watch replay -
01/27/2025Addressing health disparities at a large academic medical center: AI-driven cardiac care for aortic stenosis and mitral regurgitation
Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with severe aortic stenosis (sAS) and severe mitral regurgitation (sMR) by identifying patients who may have been previously overlooked.
Read more -
12/05/2024
Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies
Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer. Discover the significant developments that are helping to shape clinical trials and improving patient outcomes in IO and hear perspectives from industry experts on the potential of emerging therapies.
Watch replay